iBio, Inc. (IBIO) |
|
0.1703 -0.012 (-6.53%)
|
10-02 22:30 |
|
Open: |
0.1726 |
Pre. Close: |
0.1822 |
|
High:
|
0.1896 |
Low:
|
0.1651 |
|
Volume:
|
3,569,539 |
Market Cap:
|
38(M) |
|
|
|
|
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.19 - 0.19 |
0.19 - 0.19 |
|
Low:
|
0.16 - 0.16 |
0.16 - 0.17 |
|
Close:
|
0.17 - 0.17 |
0.17 - 0.17 |
|
Technical analysis |
as of: 2022-09-30 4:28:57 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.55  One year: 0.77 |
| Support: |
Support1: 0.16 Support2: 0.13 |
| Resistance: |
Resistance1: 0.47 Resistance2: 0.66 |
| Pivot: |
0.31 |
| Moving Average: |
MA(5): 0.24 MA(20): 0.3
MA(100): 0.27 MA(250): 0.42 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 1.4 %D(3): 5.9 |
| RSI: |
RSI(14): 34.4 |
| 52-week: |
High: 0.99 Low: 0.16 |
| Average Vol(K): |
3-Month: 1,801 (K) 10-Days: 3,282 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IBIO ] has closed above bottom band by 3.5%. Bollinger Bands are 239.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue. |
|
|
Headline News |
Sun, 02 Oct 2022
Camilla George – ‘Ibio-Ibio’ - LondonJazz News
Fri, 30 Sep 2022
3 Healthcare Stocks to Sell Before They Die - InvestorPlace
Wed, 28 Sep 2022
IBIO stock tumbles even as Cantor defends plans to drop COVID-19 shot (NYSE:IBIO) - Seeking Alpha
Wed, 28 Sep 2022
iBio shares are trading lower after the company reported FY22 preliminary sales results and announced a 1 - Benzinga
Wed, 28 Sep 2022
Ibio Earnings, Revenue miss in Q1 By Investing.com - Investing.com Canada
Wed, 28 Sep 2022
Ibio earnings, Revenue miss in Q1 - Investing.com India
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
218 (M) |
|
% Held by Insiders
|
2.167e+008 (%) |
|
% Held by Institutions
|
1.2 (%) |
|
Shares Short
|
11,600 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.038e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.16 |
|
EPS Est Next Year
|
-0.21 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
520.1 |
|
Return on Equity (ttm)
|
-15.9 |
|
Qtrly Rev. Growth
|
2.17e+006 |
|
Gross Profit (p.s.)
|
0.01 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.08 |
|
Qtrly Earnings Growth
|
-0.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-32 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
22.67 |
|
Price to Cash Flow
|
-2.11 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.117e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
